Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PANTHER
- 04 Jun 2024 Results (n=93) assessing the long term radiographic progression-free survival (rPFS) and overall survival (OS) for both cohorts were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 11 Jan 2024 The protocol has been amended to increase in study time fram for Median radiographic progression free survival (PFS) up to 4 years.
- 11 Jan 2024 Planned primary completion date changed from 31 Jan 2023 to 22 Feb 2025.